Ads
related to: Treatment Macular Degeneration- Hear what some Wet AMD patients had to say about their experience with EYLEA.
- Appointment Tips
Find tips that can help you prepare
for a visit with your doctor.
- Caregiver Virtual Reality
Experience for yourself what life
may be like living with Wet AMD.
Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related ...
Morningstar· 1 day agoKinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and potential advantages of KIN001 ...
NGM Biopharmaceuticals: Eye Disorder Data Due 2nd Half Of 2022 (NASDAQ:NGM)
Seeking Alpha· 4 days agoThis will be the release of results from the phase 2 CATALINA study using NGM621 for the treatment...
LumiThera Presents US LIGHTSITE III Trial Data Showing Improvement in Vision in Intermediate Dry...
WFMZ Eastern Pennsylvania and Western New Jersey· 3 days agoSEATTLE, June 22, 2022 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company...
Adverum Biotechnologies Obtains EMA’s Priority Medicines Status For Chronic Eye Disorder Candidate -...
Benzinga· 17 hours agoThe European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Adverum Biotechnologies’ ADVM lead drug ADVM-022 for the treatment of wet age-related ...
Vision changes after 40? Here's what you need to know
The Port Lavaca Wave· 10 hours agoThe American Academy of Ophthalmology (AAO) suggests everyone see an ophthalmologist for a baseline eye disease screening at age 40, even if there are no apparent problems with their vision.
Apellis (APLS) Expands Deal for Targeted Complement Therapies
Zacks via Yahoo Finance· 2 days agoApellis (APLS) expands its current research and development deal with privately held company,...
Cost of ranibizumab port delivery system for treating nAMD examined
Medical Xpress· 2 days agoFor patients with neovascular age-related macular degeneration (nAMD), ranibizumab with a port...
EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors
Morningstar· 2 days agoDr. Adamis is a highly accomplished ophthalmology executive with more than 30 years of research and development experience in the biopharmaceutical industry. “Dr. Adamis is a pioneer in the ...
Supplements warning: The vitamin linked to a ‘rapid' reduction in vision ‘over minutes'
MSN News· 5 hours agoUNLIKE drugs, supplements are not intended to treat, prevent or cure diseases, but instead are...
Kubota Vision Announced End of Phase 3 Clinical Trial of Emixustat in Patients with Stargardt...
Morningstar· 17 hours ago(Tokyo 4596), announced today the completion of the phase 3 clinical trial investigating emixustat hydrochloride (“emixustat”) in patients with macular atrophy secondary to ...
Ads
related to: Treatment Macular Degeneration
